Form 4: CRISPR Therapeutics CEO Exercises Stock Options and Acquires Shares

CRISPR Therapeutics CEO, Samarth Kulkarni, exercised stock options and acquired 13,751 common shares at a price of $16.21 per share on December 24, 2024.

Summary

• Samarth Kulkarni, the CEO of CRISPR Therapeutics, exercised stock options to acquire 13,751 common shares on December 24, 2024.
• The shares were acquired at a price of $16.21 per share.
• Following the transaction, Mr. Kulkarni directly owns 195,291 common shares.
• He also indirectly owns 85,622 common shares through The Kulkarni 2023 GRAT.
• The stock options were granted on May 3, 2017, and vested in 48 equal monthly installments starting May 31, 2017.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction of stock option exercise by the CEO, which is neither particularly positive nor negative. It's a standard part of executive compensation.

Positives

• The CEO's decision to exercise stock options and acquire shares could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This transaction is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company executives.

Comparison to Industry Standards

• Executive stock option exercises are a common practice in the biotechnology industry, often used as a form of compensation and incentive.
• Similar transactions are regularly reported by executives at companies like Editas Medicine and Intellia Therapeutics, which are also involved in gene editing technologies.
• The vesting schedule of 48 months is a typical timeframe for stock options in the industry.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates the CEO's confidence in the company.

Key Dates

Keywords

CRISPR Therapeutics, Samarth Kulkarni, stock options, common shares, insider trading, SEC Form 4, executive compensation